does tirzepatide have fewer side effects than semaglutide Comparative safety and of and tirzepatide: Implications for clinical decision-making in obesity management Ozempic vs Mounjaro: Comparing GLP‑1

A team of international researchers have now found non-diabetic patients taking glucagon-like peptide-1 receptor agonist (GLP-1 RA) drugs are at a higher risk of stomach paralysis, pancreatitis, and bowel obstructions, compared with those taking other weight loss medications

People have been mouthing off on social media about the different things that Ozempic and other glucagon-like peptide-1 receptor agonists can supposedly do to, well, the inside of your mouth

Q: Are there any synthetic chemicals in this product

however, the very short half-life of endogenous GLP-1 (12 minutes) has limited its therapeutic use